An observational study in Mouth Diseases, sponsored by Proteocyte Diagnostics Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-07.
Sponsored by Proteocyte Diagnostics Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Mouth Diseases with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Mouth Diseases · United States.
Among the 17 studies in Mouth Diseases with a site in United States, this one is the only one that started in 2023, is one of 5 observational ones, and was the 16th registered.
99 studies on the registry are indexed under Mouth Diseases; 19 are open to participants now.
Browse Mouth Diseases studies →2 of the 17 studies in Mouth Diseases with a site in United States are open now. Recruiting first, the newest first:
Ryan J. Halter · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Mouth Diseases studies recruiting now, 8 (67%) set no upper age limit and 2 (17%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 128 across 37 observational studies indexed under Mouth Diseases.
Median enrollment 290 across the 11 interventional studies, 90 across the 5 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 10 most frequent:
Proteocyte Diagnostics Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Proteocyte Diagnostics Inc. has 1 study filed under Mouth Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Mouth Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.
The study objectives are to:
The target population are patients presenting with an OPMD who have received a biopsy of their lesion. The study sample will be composed of patients with previously biopsied OPMDs from contracted clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No dysplasia, mild, moderate, severe dysplasia, CIS
Other: STRATICYTE™ Test
No dysplasia, mild, moderate, severe dysplasia, CIS
Other: STRATICYTE™ Test
Assessment for risk of progression to oral cancer
Also known as: S100A7 Immunohistochemistry Signature-based Test
Sensitivity and Specificity
Standard measures of accuracy calculated using cross-tabulation of predicted risk category and confirmed cancer progression over a 5-year period from biopsy
Time frame: 5 years
Survival analysis
Kaplan-Meier analyses to compare time to a positive diagnosis of oral cancer between patients/biopsies with a STRATICYTE™ classification of Low- and Elevated-Risk.
Time frame: 5 years
AUC
Area under the receiver operator curve
Time frame: 5 years
C-index (Harrell's)
From all possible pairs of patients, compute the number of concordant and discordant pairs. Compute C-index as the proportion of all possible pairs that are concordant.
Time frame: 5 years
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Dec 2024, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Proteocyte Diagnostics Inc.